Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ARTL
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
ARTL
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

ARTL Similar Chart Price Prediction

The price of ARTL is predicted to go up -3.64%, based on the high correlation periods with ALRS. The similarity of these two price pattern on the periods is 98.35%.

stocks logo

ARTL

stocks logo

ALRS

Down: -3.64%Similarity: 98.35%

ARTL Revenue Forecast

ARTL EPS Forecast

ARTL FAQs

What is bull’s view on ARTL?

ARTL stock has a bullish outlook due to EF Hutton's "Buy" rating with a $17 price target, implying a 1,445% upside from its current $1.21 price, driven by institutional interest and pipeline progress. The company’s advancements in ART26.12 and ART27.13 clinical trials further strengthen its growth potential. However, the lack of revenue and reliance on clinical milestones make it a high-risk, high-reward investment.

What is bear's view on ARTL?

ARTL stock currently trades at $1.08, reflecting a bearish sentiment due to its lack of revenue generation and ongoing losses. Despite positive developments in clinical trials and analyst price targets as high as $17, the stock's financial instability and speculative nature make it risky. The bearish view stems from its weak fundamentals and reliance on future trial success.

ARTL VS S&P500

Ask Intellectia about ARTL

ARTL Analyst's Forecast

Jason Kolbert

EF Hutton

Strong Buy

Price Target

$6

Upside

+445.45%

EF Hutton initiated coverage of Artelo Biosciences with a Buy rating and $6 price target. Artelo is an emerging biotechnology company focused on cachexia and chemotherapy-induced peripheral neuropathy, the analyst tells investors in a research note. The firm says the company is early in its growth phase, and raising capital will be mission-critical to realize the next series of value inflection points.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free